Evidence map›Paper›PMID 41524264›Full record

ArticleJournal of medicinal chemistry2026

From Discovery to Clinical Trial: YCT-529, an Oral NonHormonal Male Contraceptive Targeting the Retinoic Acid Receptor Alpha.

Rui Shi, Md Abdullah Al Noman, Nadja Mannowetz, Narsihmulu Cheryala, Ehfazul Haque, Soma Maitra, Tahmina Naqvi, Sanny S W Chung, Akash Bakshi, Jon E Hawkinson and 3 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Novel male contraceptives.Future science OA · 2026
    Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Rui ShiDepartment of Medicinal Chemistry and Institute for Therapeutics Discovery and Development, College of Pharmacy, University of Minnesota, 717 Delaware Street SE, Minneapolis, Minnesota 55414, United States.
Md Abdullah Al NomanDepartment of Medicinal Chemistry and Institute for Therapeutics Discovery and Development, College of Pharmacy, University of Minnesota, 717 Delaware Street SE, Minneapolis, Minnesota 55414, United States.ORCID 0000-0002-2980-0592
Nadja MannowetzYourChoice Therapeutics, 2261 Market Street, Unit 4762, San Francisco, California 94114, United States.
Narsihmulu CheryalaDepartment of Medicinal Chemistry and Institute for Therapeutics Discovery and Development, College of Pharmacy, University of Minnesota, 717 Delaware Street SE, Minneapolis, Minnesota 55414, United States.
Ehfazul HaqueDepartment of Medicinal Chemistry and Institute for Therapeutics Discovery and Development, College of Pharmacy, University of Minnesota, 717 Delaware Street SE, Minneapolis, Minnesota 55414, United States.
Soma MaitraDepartment of Medicinal Chemistry and Institute for Therapeutics Discovery and Development, College of Pharmacy, University of Minnesota, 717 Delaware Street SE, Minneapolis, Minnesota 55414, United States.
Tahmina NaqviDepartment of Medicinal Chemistry and Institute for Therapeutics Discovery and Development, College of Pharmacy, University of Minnesota, 717 Delaware Street SE, Minneapolis, Minnesota 55414, United States.
Sanny S W ChungDepartment of Genetics and Development, Columbia University Medical Center, 1150 St. Nicholas Avenue, New York, New York 10032, United States.
Akash BakshiYourChoice Therapeutics, 2261 Market Street, Unit 4762, San Francisco, California 94114, United States.
Jon E HawkinsonDepartment of Medicinal Chemistry and Institute for Therapeutics Discovery and Development, College of Pharmacy, University of Minnesota, 717 Delaware Street SE, Minneapolis, Minnesota 55414, United States.ORCID 0000-0001-5461-7071
Henry L WongDepartment of Medicinal Chemistry and Institute for Therapeutics Discovery and Development, College of Pharmacy, University of Minnesota, 717 Delaware Street SE, Minneapolis, Minnesota 55414, United States.ORCID 0000-0003-1755-1485
Debra J WolgemuthDepartment of Genetics and Development, Columbia University Medical Center, 1150 St. Nicholas Avenue, New York, New York 10032, United States.
Gunda I GeorgDepartment of Medicinal Chemistry and Institute for Therapeutics Discovery and Development, College of Pharmacy, University of Minnesota, 717 Delaware Street SE, Minneapolis, Minnesota 55414, United States.ORCID 0000-0002-8900-9460

Funding

Understanding Behavioral Patterns in Contraceptive UseP50HD093540 · NICHD · UNIVERSITY OF MINNESOTA · PI GEORG, GUNDA I. · 2019 to 2020
$3.9M
NICHD NIH HHS HHSN275201300017CNICHD NIH HHS HHSN275201300017INICHD NIH HHS P50 HD093540
6 · The paper itself

Abstract

The retinoic acid receptor alpha (RARα) has emerged as a compelling genetically and pharmacologically validated target for nonhormonal male contraception due to its essential role in spermatogenesis. In the present study, a search for specific inhibitors of RARα utilized systematic linker bioisosterism, hydrophobic core modification, and iterative structure-activity relationship refinement, identified

Indexed as

Contraceptive Agents, MaleReceptors, Retinoic AcidRetinoic Acid Receptor alphaAdministration, OralAnimalsDrug DiscoveryHumansMaleRatsRats, Sprague-DawleyStructure-Activity RelationshipContraceptive Agents, MaleReceptors, Retinoic AcidRetinoic Acid Receptor alpha

Identifiers

PMID41524264
PMCPMC12833862

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.